<DOC>
	<DOC>NCT02487446</DOC>
	<brief_summary>The purpose of this study is to demonstrate that the efficacy of the combination product QVA149 is similar to the efficacy of the combination product umeclidinium/vilanterol on a pre-specified endpoint of FEV1 AUC0-24h while maintaining an acceptable safety profile.</brief_summary>
	<brief_title>Efficacy and Safety Study of QVA149 in COPD Patients</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases, Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<mesh_term>Glycopyrrolate</mesh_term>
	<criteria>Male or female adults aged ≥40 yrs Smoking history of at least 10 pack years Diagnosis of stable Chronic Obstructive Pulmonary Disease (COPD) as classified by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) Guidelines, 2015) Postbronchodilator Forced Expiratory Volume in 1 Second (FEV1)&lt; 80% and ≥ 30% of the predicted normal value and postbronchodilator FEV1/FVC (forced vital capacity) &lt;70% Modified Medical Research Council questionnaire grade of 2 or higher Patients who have had a respiratory tract infection within 4 weeks prior to Visit 1 Patients with concomitant pulmonary disease Patients with a history of asthma Any patient with lung cancer or a history of lung cancer Patients with a history of certain cardiovascular comorbid conditions Patients with a known history and diagnosis of alpha1 antitrypsin deficiency Patients in the active phase of a supervised pulmonary rehabilitation program Patients contraindicated for inhaled anticholinergic agents and β2 agonists Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Chronic Obstructive Pulmonary Disease (COPD)</keyword>
</DOC>